

Application No.: 10/524,395

Docket No.: ALXN-P01-093

AMENDMENTS TO THE SPECIFICATION

RECEIVED
CENTRAL FAX CENTER

OCT 17 2008

Please replace the paragraph [0047] on page 4 with the following re-written paragraph:

[0047] Preferably, a monoclonal antibody against the C-type lectin(s) on dendritic or macrophage cells is used, more specifically against DC-SIGN or an antigenic part thereof. Hereinbelow, the invention will be illustrated by means of monoclonals herein referred to as AZN-D1, AZN-D2, and AZN-D3 although similar monoclonals with comparable specificity for C-type lectins may also be used. Hybridomas that produce the monoclonals AZN-D1 and AZN-D2 were deposited on April 8, 1999 with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom, under ~~provisional~~-ECACC accession numbers 99040818 and 99040819, respectively. A hybridoma that produces AZN-D3 was deposited on July 18, 2003 with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom, under ECACC accession number 03071801. Antibodies against the C-type lectins on dendritic cells, specifically against DC-SIGN, have been described by WO 00/63251.